Advanced

Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.

Eriksson, Sophie LU ; Ohlsson, Tomas G LU ; Nilsson, Rune LU and Tennvall, Jan (2012) In Cancer Biotherapy & Radiopharmaceuticals 27(3). p.175-182
Abstract
Metastatic disease after successful treatment of the primary tumor continues to be a therapeutic challenge. Enhancement of therapeutic effects by the administration of unlabeled monoclonal antibodies (mAbs) after radioimmunotherapy (RIT) may provide a means of preventing or delaying the development of metastatic disease. In the present study, Brown Norway rats with syngeneic grafted colon carcinomas were administered the minimal effective therapeutic dose of 400 MBq/kg lutetium-177 ((177)Lu)-DOTA-BR96. After 2 weeks, half of the animals were given 15 mg/kg unlabeled mAb BR96 as consolidation therapy. Treatment response and toxicity were monitored 100 days after the treatment with unlabeled BR96. The treatment with unlabeled mAb after RIT... (More)
Metastatic disease after successful treatment of the primary tumor continues to be a therapeutic challenge. Enhancement of therapeutic effects by the administration of unlabeled monoclonal antibodies (mAbs) after radioimmunotherapy (RIT) may provide a means of preventing or delaying the development of metastatic disease. In the present study, Brown Norway rats with syngeneic grafted colon carcinomas were administered the minimal effective therapeutic dose of 400 MBq/kg lutetium-177 ((177)Lu)-DOTA-BR96. After 2 weeks, half of the animals were given 15 mg/kg unlabeled mAb BR96 as consolidation therapy. Treatment response and toxicity were monitored 100 days after the treatment with unlabeled BR96. The treatment with unlabeled mAb after RIT resulted in a complete response (CR) in 19 of 19 animals, while RIT alone resulted in a CR in 17 of 19 animals. The additional treatment did not affect the number of animals with metastatic disease or the time to clinical symptoms of metastases. RIT resulted in reversible myelotoxicity. The unlabeled mAb BR96 did not cause any additional toxicity, making it possible to repeat the consolidation therapy. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
colon carcinoma, radioimmunotherapy, lutetium-177, immunotherapy, antibody therapy, syngeneic tumor model
in
Cancer Biotherapy & Radiopharmaceuticals
volume
27
issue
3
pages
175 - 182
publisher
Mary Ann Liebert, Inc.
external identifiers
  • wos:000302573700001
  • pmid:22417248
  • scopus:84859609657
ISSN
1557-8852
DOI
10.1089/cbr.2011.1132
language
English
LU publication?
yes
id
1de6f07c-e471-4b1b-948a-b90fdd30ffc1 (old id 2431847)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22417248?dopt=Abstract
date added to LUP
2012-04-03 10:51:22
date last changed
2017-06-25 04:05:15
@article{1de6f07c-e471-4b1b-948a-b90fdd30ffc1,
  abstract     = {Metastatic disease after successful treatment of the primary tumor continues to be a therapeutic challenge. Enhancement of therapeutic effects by the administration of unlabeled monoclonal antibodies (mAbs) after radioimmunotherapy (RIT) may provide a means of preventing or delaying the development of metastatic disease. In the present study, Brown Norway rats with syngeneic grafted colon carcinomas were administered the minimal effective therapeutic dose of 400 MBq/kg lutetium-177 ((177)Lu)-DOTA-BR96. After 2 weeks, half of the animals were given 15 mg/kg unlabeled mAb BR96 as consolidation therapy. Treatment response and toxicity were monitored 100 days after the treatment with unlabeled BR96. The treatment with unlabeled mAb after RIT resulted in a complete response (CR) in 19 of 19 animals, while RIT alone resulted in a CR in 17 of 19 animals. The additional treatment did not affect the number of animals with metastatic disease or the time to clinical symptoms of metastases. RIT resulted in reversible myelotoxicity. The unlabeled mAb BR96 did not cause any additional toxicity, making it possible to repeat the consolidation therapy.},
  author       = {Eriksson, Sophie and Ohlsson, Tomas G and Nilsson, Rune and Tennvall, Jan},
  issn         = {1557-8852},
  keyword      = {colon carcinoma,radioimmunotherapy,lutetium-177,immunotherapy,antibody therapy,syngeneic tumor model},
  language     = {eng},
  number       = {3},
  pages        = {175--182},
  publisher    = {Mary Ann Liebert, Inc.},
  series       = {Cancer Biotherapy & Radiopharmaceuticals},
  title        = {Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with (177)Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model.},
  url          = {http://dx.doi.org/10.1089/cbr.2011.1132},
  volume       = {27},
  year         = {2012},
}